Laforin Negatively Regulates Cell Cycle Progression through Glycogen Synthase Kinase 3β-Dependent Mechanisms

REFERENCES

• Aberle, H., A. Bauer, J. Stappert, A. Kispert, and R. Kemler. 1997. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16:3797–3804.
   PubMed Web of Science ®Google Scholar
• Ali, A., K. P. Hoeflich, and J. R. Woodgett. 2001. Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev. 101:2527–2540.
   PubMedGoogle Scholar
• Alt, J. R., J. L. Cleveland, M. Hannink, and J. A. Diehl. 2000. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14:3102–3114.
   PubMed Web of Science ®Google Scholar
• Behrens, J., B. A. Jerchow, M. Wurtele, J. Grimm, C. Asbrand, R. Wirtz, M. Kuhl, D. Wedlich, and W. Birchmeier. 1998. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280:596–599.
   PubMed Web of Science ®Google Scholar
• Chan, E. M., C. A. Ackerley, H. Lohi, L. Ianzano, M. A. Cortez, P. Shannon, S. W. Scherer, and B. A. Minassian. 2004. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum. Mol. Genet. 13:1117–1129.
   PubMedGoogle Scholar
• Cohen, P., and S. Frame. 2001. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2:769–776.
   PubMed Web of Science ®Google Scholar
• Diehl, J. A., M. Cheng, M. F. Roussel, and C. J. Sherr. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:3499–3511.
   PubMed Web of Science ®Google Scholar
• Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443–450.
   PubMed Web of Science ®Google Scholar
• Ewen, M. E., H. K. Sluss, C. J. Sherr, H. Matsushime, J. Kato, and D. M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487–497.
   PubMed Web of Science ®Google Scholar
• Ganesh, S., K. L. Agarwala, K. Ueda, T. Akagi, K. Shoda, T. Usui, T. Hashikawa, H. Osada, A. V. Delgado-Escueta, and K. Yamakawa. 2000. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum. Mol. Genet. 9:2251–2261.
   PubMed Web of Science ®Google Scholar
• Ganesh, S., A. V. Delgado-Escueta, T. Sakamoto, M. R. Avila, J. Machado-Salas, Y. Hoshii, T. Akagi, H. Gomi, T. Suzuki, K. Amano, K. L. Agarwala, Y. Hasegawa, D. S. Bai, T. Ishihara, T. Hashikawa, S. Itohara, E. M. Cornford, H. Niki, and K. Yamakawa. 2002. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. 11:1251–1262.
   PubMed Web of Science ®Google Scholar
• Grimes, C. A., and R. S. Jope. 2001. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65:391–426.
   PubMed Web of Science ®Google Scholar
• Guan, K. L., C. W. Jenkins, Y. Li, M. A. Nichols, X. Wu, C. L. O'Keefe, A. G. Matera, and Y. Xiong. 1994. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:2939–2952.
   PubMed Web of Science ®Google Scholar
• Guan, K. L., C. W. Jenkins, Y. Li, C. L. O'Keefe, S. Noh, X. Wu, M. Zariwala, A. G. Matera, and Y. Xiong. 1996. Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol. Biol. Cell 7:57–70.
   PubMedGoogle Scholar
• Hoeflich, K. P., J. Luo, E. A. Rubie, M. S. Tsao, O. Jin, and J. R. Woodgett. 2000. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86–90.
   PubMed Web of Science ®Google Scholar
• Leone, G., J. DeGregori, Z. Yan, L. Jakoi, S. Ishida, R. S. Williams, and J. R. Nevins. 1998. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev. 12:2120–2130.
   PubMed Web of Science ®Google Scholar
• Lohi, H., L. Ianzano, X. C. Zhao, E. M. Chan, J. Turnbull, S. W. Scherer, C. A. Ackerley, and B. A. Minassian. 2005. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum. Mol. Genet. 14:2727–2736.
   PubMedGoogle Scholar
• Matsushime, H., M. E. Ewen, D. K. Strom, J. Y. Kato, S. K. Hanks, M. F. Roussel, and C. J. Sherr. 1992. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71:323–334.
   PubMed Web of Science ®Google Scholar
• Meijer, L., A. L. Skaltsounis, P. Magiatis, P. Polychronopoulos, M. Knockaert, M. Leost, X. P. Ryan, C. A. Vonica, A. Brivanlou, R. Dajani, C. Crovace, C. Tarricone, A. Musacchio, S. M. Roe, L. Pearl, and P. Greengard. 2003. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 10:1255–1266.
   PubMed Web of Science ®Google Scholar
• Minassian, B. A., D. M. Andrade, L. Ianzano, E. J. Young, E. Chan, C. A. Ackerley, and S. W. Scherer. 2001. Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase. Ann. Neurol. 49:271–275.
   PubMedGoogle Scholar
• Minassian, B. A., L. Ianzano, M. Meloche, E. Andermann, G. A. Rouleau, A. V. Delgado-Escueta, and S. W. Scherer. 2000. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 55:341–346.
   PubMed Web of Science ®Google Scholar
• Minassian, B. A., J. R. Lee, J. A. Herbrick, J. Huizenga, S. Soder, A. J. Mungall, I. Dunham, R. Gardner, C. Y. Fong, S. Carpenter, L. Jardim, P. Satishchandra, E. Andermann, O. C. Snead III, I. Lopes-Cendes, L. C. Tsui, A. V. Delgado-Escueta, G. A. Rouleau, and S. W. Scherer. 1998. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 20:171–174.
   PubMed Web of Science ®Google Scholar
• Narita, M., S. Nunez, E. Heard, A. W. Lin, S. A. Hearn, D. L. Spector, G. J. Hannon, and S. W. Lowe. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703–716.
   PubMed Web of Science ®Google Scholar
• Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J. 2004. Principles of tumor suppression. Cell 116:235–246.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and F. McCormick. 2002. The RB and p53 pathways in cancer. Cancer Cell 2:103–112.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Sinha, D., Z. Wang, K. L. Ruchalski, J. S. Levine, S. Krishnan, W. Lieberthal, J. H. Schwartz, and S. C. Borkan. 2005. Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am. J. Physiol. Renal Physiol. 288:F703–F713.
   PubMed Web of Science ®Google Scholar
• Stacey, D. W. 2003. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol. 15:158–163.
   PubMed Web of Science ®Google Scholar
• Thornton, T. M., G. Pedraza-Alva, B. Deng, C. D. Wood, A. Aronshtam, J. L. Clements, G. Sabio, R. J. Davis, D. E. Matthews, B. Doble, and M. Rincon. 2008. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 320:667–670.
   PubMed Web of Science ®Google Scholar
• Tseng, A. S., F. B. Engel, and M. T. Keating. 2006. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem. Biol. 13:957–963.
   PubMed Web of Science ®Google Scholar
• Wang, Y., Y. Liu, C. Wu, H. Zhang, X. Zheng, Z. Zheng, T. L. Geiger, G. J. Nuovo, Y. Liu, and P. Zheng. 2006. Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell 10:179–190.
   PubMedGoogle Scholar
• Xiong, Y., T. Connolly, B. Futcher, and D. Beach. 1991. Human D-type cyclin. Cell 65:691–699.
   PubMed Web of Science ®Google Scholar
• Xiong, Y., H. Zhang, and D. Beach. 1993. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 7:1572–1583.
   PubMed Web of Science ®Google Scholar